Fosamax Femur Fracture Lawsuit
Settlement Master appointed over Fosamax litigation

On November 22, U.S. District Judge John F. Keenan appointed well-respected law professor John D. Feerick, Dean Emeritus of the Fordham University School of Law, to oversee the settlement of Fosamax lawsuits filed across the U.S. against Merck, the maker of the drug. Plaintiffs say that Merck failed to properly warn about the side effects associated with long term use.

Feerick is expected to attempt to facilitate a Fosamax settlement agreement between Merck and plaintiffs.  Complaints brought against the company claimed that taking Fosamax caused plaintiffs to suffer from decay of the jaw bone, known as osteonecrosis (ONJ). Others claimed that the drug causes atypical femur fractures which, according to reports, occured during ordinary activities like walking or jogging.

On January 7, 2008, the U.S. Food and Drug Administration issued a medical advisory warning doctors and patients about the side effects of Fosamax use. Two years later, the FDA mandated new warning labels for all bisphosphonate drugs, including Fosamax. Researchers who have studied bisphosphonates drugs say that Fosamax was shown to slow down the rate at which the human body replaces old bones with new, causing micro fractures to eventually become major fractures. This process, known as bone turnover suppression, is what causes the femur to fracture.

Those who have taken the drug continue to pursue compensation by filing Fosamax lawsuits against Merck. Victims accuse the drug company of failing to properly warn about the risks associated with long term use of Fosamax, but Merck counters these accusations by stating that no results of the side effects were discovered in their clinical trials prior to releasing the drug.



About the Contributor

Related Posts